P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease
B. Feagan, B E Sands(Icahn School of Medicine at Mount Sinai), Stephen B. Hanauer(Northwestern University), Simon Lichtiger(Mount Sinai Medical Center), Paul Rutgeerts(KU Leuven), Gahl Greenberg(Mount Sinai Hospital), Cynthia Guzzo(Janssen (Belgium)), C.F. Chiou(Janssen (Belgium)), Ling Gao(Wuhan University), Stefanie Schreiber(Otto-von-Guericke-Universität Magdeburg), Subrata Ghosh, Mikhail Blank(Janssen (Belgium)), W. Sandborn, Ş. Targan(Cedars-Sinai Medical Center), W de Villiers(University of Cape Town), Remo Panaccione(University of Calgary), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 9
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k